Author’s response to reviews

Title: RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis

Authors:

Lin Yang (lyang69@sina.com)
Anna Alyasova (alyasovaav68@mail.ru)
Dingwei Ye (dwyeli@163.com)
Antonia Ridolfi (antonia.ridolfi@novartis.com)
Luca Dezzani (luca.dezzani@novartis.com)
Robert Motzer (Motzer@mskcc.org)

Version: 2 Date: 18 Dec 2017

Author’s response to reviews:

December 18, 2017

Editorial board

BMC Cancer

Re: Submission to BMC Cancer - BCAN-D-17-01078R1

Dear BMC Cancer Editorial Board,

I would like to thank the editor and reviewers of BMC Cancer for taking the time to review and improve my recently submitted manuscript “RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis” for publication. The following is a description of the revisions I have made based on the editor’s comments. Both reviewers had no further comments following the first resubmission.
COMMENTS FROM THE EDITOR

Comment 1: Please add a trial registration subsection to your abstract: https://bmccancer.biomedcentral.com/submission-guidelines/preparing-your-manuscript/research-article

Response 1: I have removed the ‘Clinical trial name and identifier’ section from the cover page, and added a ‘Trial Registration’ subsection to the abstract (Abstract, page 3, lines 70–72):

“Trial registration: Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma (RECORD-4); ClinicalTrials.gov identifier: NCT01491672. Registration date: December 14, 2011”

Comment 2: On uploading your revisions, please remove all tracking/highlighting and instead upload a single clean version of the manuscript.

Response 2: I will upload a single clean version of the manuscript upon addressing these revisions

Comment 3: Please place the 'List of abbreviations' after the 'Conclusion'.

Response 3: The ‘List of Abbreviations’ has been shifted to follow the ‘Conclusion’ section (page 8, lines 165–171)

Comment 4: Authors' contributions (within declarations) - please add the phrase: 'All authors read and approved the final manuscript.'.

Response 4: This phrase has been added to the ‘Author Contributions’ section within the ‘Declarations’ section (page 9, line 201)

Comment 5: Under Funding (within declarations) - please add the phrase: 'The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript'.
Response 5: This phrase has been added to the ‘Funding’ section within the ‘Declarations’ section (page 9, lines 190–191)

Comment 6: Please remove the figures from the main text and only upload them as separate files in the submission system. Please ensure also that all figures have been cited in the main manuscript.

Response 6: Figures have been removed from the main text and will be submitted separately. I confirm that all figures are cited in the main text of the manuscript.

Thank you for your time and consideration. I look forward to hearing from you.

Kind regards,

Lin Yang, M.D.
Medical Department of Cancer Hospital
Chinese Academy of Medical Sciences
No. 17, Panjiayuannanli, Chaoyang District
Beijing, China 100021
Phone (mobile): 13681015148
Fax: 86-10-67734107
Email: lyang69@sina.com